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Nowadays, biomedical applications of gold nanoparticles coupled with Epidermal Growth Factor
have attracted huge attention because of its theranostic activity, which could be useful for diag-
nosis and treatment of neurodegenerative diseases. Therefore, there is a great interest to know
the nature of the intermolecular interactions between the gold nanoparticles and epidermal growth
factor (EGF). A two-step synthesis was performed. In the first step, gold nanoparticles were synthe-
sized by chemical reduction of tetrachloroauric acid using sodium citrate as reducing and capping
agent. Secondly, gold nanoparticles were coupled with EGF. The obtained nanoparticles were char-
acterized by ultraviolet-visible spectroscopy, transmission electron microscopy, X-ray photoelectron
spectroscopy and zeta-potential before and after being coupled with the EGF. Gold nanoparticles
with an average diameter of 8.09 nm were obtained. After coupled with EGF, the particle average
diameter increased to 9.14 nm. X-ray photoelectron spectroscopy showed an electrostatic interac-
tion between gold nanoparticles and EGF. Zeta potential corroborated these results. Thus, it was
possible for the first time to identify the interactions between these two chemical species. Since
gold nanoparticles may act as carriers of EGF, these results illustrate the great potential for the use
of this bionanocomposite in neurodegenerative disease treatment.
Keywords: Electrostatic Interactions, Coupling Gold Nanoparticles, Epidermal Growth Factor,
Neurodegenerative Disease, Bionanocomposite.
1. INTRODUCTION
Biomedical applications of nanotechnology include deliv-
ery of drugs;12 detection of molecules, organisms and
viruses;3 controlled drugs targeting; diagnosis by magnetic
resonance imaging;4 treatment of neurodegenerative dis-
eases such as cancer, diabetes mellitus, among others.5
The epidermal growth factor (EGF) is involved in various
stages of cell proliferation, tissue regeneration, cell sur-
vival and more.6 Recent studies support the hypothesis that
low EGF levels detected in cerebrospinal fluid of patients
with multiple sclerosis diagnose may be causally related to
the disease.78 In fact, EGF strongly promotes the prolifer-
ation and migration of oligodendrocytes (the major func-
tion of these cells is the formation of myelin), in both,
∗Author to whom correspondence should be addressed.
physiological and pathological conditions.910 Therefore,
it has been suggested that myelin-related to EGF may
improve the remyelination process in multiple sclerosis or
other demyelinating diseases.11
EGF possesses three disulfide bridges, peptide bonds
and a free amino  group at the beginning of the chain.
Besides, EGF has an arginine carboxy group in their
 form; it is heat stable and is inactivated at 40 C.12 The
protein structure of the EGF is shown in Figure 1.
Gold nanoparticles (AuNPs) have physical, chemical
and biological properties that are related to their size and
morphology; the understanding of these tailoring proper-
ties is essential for the AuNPs applications.13 Recently,
one of the most common methods of NPs synthesis is
the chemical reduction of a gold precursor salt using
sodium citrate as reducing and capping agent. Turke-
vich, in 1951, reported the basic experimental approach
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Fig. 1. Epidermal growth factor (EGF) representation.
to produce AuNPs and described the effect of temperature
and sodium citrate concentration on the size of nanoparti-
cles. These nanoparticles can be easily functionalized with
a wide range of ligands (antibodies, polymers, diagnostic
probes, drugs, genetic material, etc.).14–16
Hybrid nanoparticles (with organic and inorganic parts)
have emerged as a simple solution for the generation
of theranostic systems.17 Thus, the design of this type
of nanoparticles has been an important source of such
systems.16 In addition, the frequency of plasmon surface
resonance of the gold nanoparticles is closely related to
system properties such as size, shape, miscibility, binder,
dielectric properties, surface functionalization and the
refractive index of the surrounding medium.18
Today, there are numerous studies on conjugation of
molecules like EGF to metallic nanoparticles (Au, Pt,
Ag, Fe2O3). The EGF delivery is a beneficial method for
chronic degenerative diseases diagnosis and treatment in
terms of targeted therapy.19 Due to this, the nanoparticles
have a high surface area to volume-ratio.20 Therefore, to
determine the synthesis and chemical properties of this
biocomposite is an important step to the development of
AuNPs with clinical applications.16
A variety of chemical functional groups that could inter-
act with the AuNPs, including imidazole, sulfur, aromatic
rings, amine, and carboxylate groups, have been estab-
lished in the literature. Different kinds of interactions
between gold and sulfur, gold and thiols, among others,
have been identified.2122 Furthermore, at the nanoscale,
the AuNPs also exhibit electrostatic interactions with the
amine groups.23 Whereas, the amine groups establish simi-
lar interactions with carboxyl groups present on the surface
of AuNPs that have been capped with sodium citrate.24–26
The main aim of the present study was to synthesize
AuNPs by chemical reduction of tetrachloroauric acid,
using sodium citrate as reducing and capping agent, and
the further coupling of the AuNPs with EGF, to determine
the kind of the interactions between them.
2. MATERIALS AND METHODS
2.1. Synthesis of AuNPs
The AuNPs were synthesized using the citrate reduction
method from a 1% HAuCl4 colloidal suspension. Firstly,
100 ml of deionized H2O were heated to boiling point and
then, 5.0 ml of sodium citrate solution (0.05 M in 50 ml
of deionized H2O) were quickly added into the flask and
stirred into solution for at least 20 min until a ruby-red
color solution was obtained.24
2.2. Preparation of Coupling AuNPs-EGF
The AuNPs coated with EGF were prepared according to
the method described by Sokolov, et al., 2006. The AuNPs
were diluted in HEPES buffer solution at 20 mM (pH 7.4,
Sigma-Aldrich) until a final optical density of 0.8 at
530 nm was obtained. Subsequently, 50 l of EGF (Sigma-
Aldrich) were diluted in 500 l of the same HEPES buffer
solution. Then, 10 ml of the solution previously prepared
of AuNPs in colloidal solution were mixed with the diluted
solution of EGF for 20 min. Afterwards, 0.5 ml of 1%
polyethylene glycol (MW= 4000, Boehringer) were added
to the mixture to prevent aggregation and the mixture
was centrifuged at 6000 rpm for 18 min. Finally, the bio-
composite (AuNPs-EGF) was redispersed in PBS buffer
(pH 7.4) and stored at 4 C.
2.3. Characterization of the AuNPs Before and
After Their Coupling with EGF
The optical properties of the AuNPs before and after their
coupling with EGF were determined using UV-Vis spec-
troscopy (Varian Cary 5000 UV-Vis-NIR, Agilent Tech-
nologies, UK). Two samples were prepared and diluted,
1 ml of AuNPs and 1 ml of biocomposite (AuNPs-EGF)
in deionized water, each one for separate characteriza-
tion. Then, each sample was analyzed in a range of 200–
800 nm in the absorption mode. Structural properties of
the nanoparticles formed, such as morphology, size and
particle distribution were characterized using a Transmis-
sion Electron Microscope (TEM) (JEOL-2100 200 kV
with LaB6 filament). A drop of the AuNPs and a drop
of the biocomposite (AuNPs-EGF) were placed on grids
and allowed to dry for 20 min before the analysis. FTIR
analysis was performed (Bruker, Model 27) to investigate
and characterize functional groups that are present in the
EGF, to verify the presence of AuNPs in the biocompos-
ite (AuNPs-EGF) and to elucidate the interactions between
the AuNPs and the EGF. FTIR technique was carried out
by placing a drop of each sample on the analysis device
and operating under standard conditions.
Zeta potential measurements were determined using the
Zetasizer 2000 (Malvern Instruments Ltd., Worcestershire,
UK). The voltage applied to driving electrodes of the cell
was 150 V of capillary electrophoresis. The sample was
prepared by injecting approximately 2 ml of solution in
the cell.
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To determine the interactions between the functional
groups of EGF and the surface of the AuNPs, the bio-
composite was analyzed by X-ray photoelectron spec-
troscopy (XPS). XPS spectra were acquired using a JEOL
JPS-9200, equipped with an X-ray source Mg (1253.6 eV)
at 300 W, the area of analysis was 3 mm2, and vacuum
was of the order of 75× 109 Torr for all samples. The
spectra were analyzed using the included software with the
instrument specsurfTM in all load spectra were corrected
by signal accidental carbon (C 1s) to 284.5 eV. The Shirley
method was used for background subtraction, while the
curve was used to the Gauss-Lorentz.
3. RESULTS AND DISCUSSION
3.1. Synthesis of AuNPs
The obtained AuNPs give rise to a ruby red colloidal solu-
tion. This color is attributed to the size and spherical shape
of the AuNPs nanoparticles. In contrast, the Au nanorods
show different colors in solution, according to the reported
by El-Sayed et al.24 More recent studies have shown that
the color of the colloidal solution is due to various con-
ditions: size, shape, crystallinity, interparticle interactions,
and the collective oscillation of electrons in the conduc-
tion band, which is known as surface plasmon oscillation27
and the dielectric constant of the surrounding medium.28
As a result, the solvent used will have an effect on the
oscillation frequency due to the varying ability of the sur-
face to accommodate the electron charge density from the
nanoparticles.29
3.2. Coupling of AuNPs with EGF
The coupling of AuNPs with EGF can be distinguished
by a precipitate formation after the mixture is cen-
trifuged, which from this point will be referred as the
bionanocomposite. The main characteristics of this bio-
nanocomposite are the sensitivity to changes of pH and to
high temperatures; when the ambient temperature exceeds
40 C, the EGF protein is denaturalized.30 Therefore, the
mixture must be stored at 4 C to avoid denaturalization
and maintain the pH of the solution during the coupling
process though the addition of HEPES buffer solution.
3.3. UV-Vis Analysis
In the UV-Vis spectrum of the AuNPs (Fig. 2) a sin-
gle peak of maximum absorption is observed at 520 nm.
According to that reported by El-Sayed et al.,24 a maxi-
mum absorbance peak at 530 nm corresponds to a gold
particle size of 40 nm. Sokolov et al. 200831 reported a
maximum absorption peak at 540 nm, obtaining AuNPs
with an average particle size of 50 nm. Liz-Marzán et al.,27
and Eustis et al.,29 demonstrated that the number of peaks
represents the morphology of nanoparticles, which means
that the presence of a single peak refers to a spherical mor-
phology. In contrast, if the spectrum shows the presence
Fig. 2. UV-visible spectra; (curve 1) bionanocomposite (EGF-AuNPs),
(curve 2) AuNPs.
of two absorbance bands, it means that the morphology
correspond to the nanorods shape.27 Due to the aforemen-
tioned, it is possible to assume that the morphology of the
AuNPs synthesized is spherical. By analyzing the different
absorption peaks previously reported, it was determined
that variations depend directly on the added amount of
sodium citrate and the concentration of HAuC4. Due to
this, the intensity of absorption in the spectrum is affected
by the size of the nanoparticles. If the maximum absorp-
tion peak was observed and a red-shift of a few nanome-
ters occurs, this indicates an increase in the size of the
nanoparticles. This event is due to the collective oscillation
of electrons in an electromagnetic field, since the larger the
size of the nanoparticle a higher oscillation is registered as
consequence.2432
In the UV-Vis spectrum of the bionanocomposite
AuNPs-EGF (Fig. 1), a red-shift of 6 nm was observed
in comparison to the AuNPs spectrum (Fig. 2) without
EGF.33 This shift was associated to the core obtained when
the nanoparticles are functionalized with other agents,
in this case, with proteins. In addition, another possible
explanation for that event may be the aggregations of NPs
as a result of surface modification,34 instead of the simple
change of size of the functionalized nanoparticle.
3.4. TEM Analysis
In the TEM micrographs (Fig. 3) the presence of AuNPs
synthesized from sodium citrate is observed, and a spher-
ical morphology can be seen. In addition, it was con-
firmed that the nanoparticles exhibit a uniform distribution
without agglomerates. In the SAED (Fig. 3), the measure-
ments of the interplanar distances correspond to the planes
(111), (220) and (311) in accordance with the structure
the face centered cubic of metallic gold which correspond
to JCPDS file: 004-0784. In the bionanocomposite’s TEM
micrographs (Fig. 3), a good distribution of particle sizes is
observed; besides, the AuNPs maintain their morphology
J. Bionanosci. 11, 1–7, 2017 3
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Fig. 3. TEM observations. (a) Micrograph of AuNPs (c) the X-ray diffraction pattern, (b) micrograph of binonanocomposite (EGF-AuNPs), insets
show the particles size distribution.
even after coupled with EGF. The histogram (Fig. 3) shows
an increase in average particle size compared to the size of
the NPs obtained before coupling. The size of the AuNPs
was 8.09 nm, with a standard deviation of 3.60 nm. After
coupling the AuNPs with EGF, the average particle size
was 9.14 nm with a standard deviation of 5.28 nm. How-
ever, this increase in size was expected by molecular cou-
pling in the Au-EGF NPs to different substances, such as
PEG, PBS, and HEPES; which ensured the stability of the
bionanocomposite (AuNPs-EGF). The size of the particles
obtained in our study, less than 50 nm, can provide better
optical properties35 and biocompatibility.2432
3.5. Structural Characterization of the EGF
with and Without Coupling to AuNPs
Usually, a FTIR spectrum of a protein is considered as a
linear sum of the spectrum of its conformational changes.
There are numerous well-established correlations between
many infrared spectra for certain protein structures.36 As
it is shown in Figure 4, the usual bands for a protein are
found. The structure of proteins, such as EGF, is char-
acterized by nine absorption bands in the infrared.3637
These bands were assigned as follows, the band found
in 3325 cm−1 was assigned to the characteristic vibra-
tion of NH group.38 The bands located at 1652 cm−1
and 1618 cm−1 are associated with the amides I and II,39
which are considered the most important bands of skele-
tal vibration of proteins. The amide I band (between
1700–1600 cm−1) is the most sensitive of all. This band is
associated with the stretching vibration of C O group of
the peptide bond. Regarding the amide II band, it is mainly
associated with the vibration in the plane of the NH group
(flexion) and the group CN (stretching).4041 Small vibra-
tion bands are observed at 1397 cm−1 1260 cm−1,41 which
correspond to the amides III. The vibrational bands amino
groups and carboxyl groups are located in 1584 cm−1 and
1460 cm−1, respectively. These groups are characteristic
of amino acids containing the protein.42
As shown in Figure 4, the spectra of the bionanocom-
posite, the OH groups of HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic) are located at 3446 cm−1 and
an intense band at 1179 cm−1 corresponding to the sul-
fonic group is observed. In addition, the second band at
1074 cm−1 corresponding to the vibrations of ether group
C–O–C, which is the most characteristic absorption band
for molecules of PEG shows a strong signal.43 This band
is also associated with the C–N vibration present in this
protein.
3.6. Characterization by X-ray Photoelectron
Spectroscopy (XPS) and Zeta Potential
Per the nature of the synthesis of the AuNPs, it was
expected that the NPs were surrounded by a layer of
sodium citrate. This is confirmed by the value of zeta
potential at −30 mV for AuNPs, which effectively means
Fig. 4. FITR spectra of de protein EGF and bionanocomposite (EGF-
AuNPs).
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that the nanoparticles could have a layer of citrate
molecules and these molecules help to maintain the sta-
bility of the nanoparticles in aqueous solution.4445 When
the bionanocomposite of AuNPs-EGF is synthesized, the
EGF molecules, by their chemical nature, carry out two
main processes for attaching to AuNPs (which are passi-
vated with citrate). The first process involves the electro-
static interaction between the carboxylate groups from the
citrate and the ammonium functional groups in EGF, or
some other functional group with cationic character that
could have been generated during the experimental pro-
cedure for coupling. This electrostatic interaction between
biomolecules (proteins) and passivating agents (citrate
molecules) of metal nanoparticles has been previously rec-
ognized by other researchers.4647 This first type of interac-
tion can be associated to the value of −7 mV obtained by
zeta potential for the bionanocomposite. Clearly, the mag-
nitude of the negative charge that exists in the carboxy-
lates of the citrate molecules surrounding the AuNPs is
reduced considerably when the coupling with EGF occurs.
This phenomenon is mainly due to the electrostatic interac-
tion between carboxylates and cationic functional groups,
which was generated during the coupling that, in turn,
reduces the negative charge on the surface of AuNPs-
EGF. Moreover, in this first interface, the EGF molecules
Fig. 5. XPS spectra: (a) Au 4f 7/2 region of AuNPs solution, (b) Au 4f 7/2 region of bionanocomposite (AuNPs-EGF), (c) N 1s region of EGF
protein, (d) N 1s region of Bionanocomposite (AuNPs-EGF).
interact, also electrostatically, with the AuNPs atoms dur-
ing coupling, as reported in previous studies of coupled
AuNPs with other biomolecules.34 This second type of
interaction or attachment can be corroborated by the peaks
obtained in the XPS spectra of Au 4f 7/2 and of N 1s.
To this end, AuNPs, EGF and bionanocomposite (AuNPs-
EGF) samples were analyzed. In Figure 5(a), two peaks
can be observed, one of them is located at 83.39 eV, cor-
responding to 7/2 4f Au0, and the other peak, located
at 82.66 eV, corresponds to a satellite peak 5 of Si 2p
3/2 that interferes with the gold region. At the same time,
it was after deconvolution in the region 4f 7/2 Au0 of
the bionanocomposite (AuNPs-EGF) that three peaks were
obtained (Fig. 5(b)). The peaks located at 83.01 eV and
83.39 eV (Fig. 5(b)) are attributed to Au0. In the spec-
trum of the bionanocomposite occurs a displacement of
0.38 eV of this signal compared to the same peak obtained
for the AuNPs only. This displacement can be attributed
to the electrostatic interaction between atoms from the
AuNPs with the nitrogen from the amine groups of the
EGF protein. This type of interaction has been identi-
fied by other authors.344849 The third peak is observed
at 83.84 eV (Fig. 6), which may be related to a possible
oxidation of the AuNPs when coupled with EGF. Some
reports have attributed the emergence of new peaks at
J. Bionanosci. 11, 1–7, 2017 5
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higher binding energy to an oxidative reaction when gold
is functionalized.48
Currently, a variety of functional groups that could inter-
act with the AuNPs are known, including imidazole, sulfur,
aromatic rings, amine and carboxylates.50 In our study, we
recognized the presence of zwitterions in EGF molecule
located at a terminal end of the protein chain and formed
by five basic amino acids. This protein possesses four
amino acids of ARG (arginine) and one amino acid of HIS
(histidine),51 as is shown in Figure 1.
In order to further demonstrate the interaction occur-
ring between Au and nitrogen moieties present in EGF, the
N 1s region of XPS spectrum was deconvoluted. The spec-
trum in the N 1s region corresponding to EGF is shown in
Figure 21(c), the peak located at 400.24 eV is consistent
with the binding energy of the amine group.38 The second
peak with lower intensity at 401.17 eV is associated with
the binding energy of protonated amines. In the XPS spec-
trum of the bionanocomposite (AuNPs-EGF) as illustrated
in Figure 21(d), there is a shift of this last signal (0.38 eV),
which can be attributed to the electrostatic interaction
between the nitrogen atoms of protonated amines of the
protein with the AuNPs. This type of interaction is in con-
cordance with the ones proposed by other authors.22344952
Furthermore, similar energy changes have been observed
when the AuNPs system is functionalized, indicating a
physical absorption.4953
Other studies described that due to the AuNPs cou-
pling with other proteins.22 So, extra peaks appear with
lower intensity but higher binding energy, they provide an
increase of 0.8 eV.22 In our system, the binding energy
was 0.77 eV, which is consistent with previous find-
ings of interactions between metallic nanoparticles and
biomolecules. This event excludes the possibility of inter-
actions with thiol groups because the sulfur found between
the cysteinemolecules forms disulfide bridges. Methion-
ine is another amino acid that could interact with AuNPs.
However, there is only one of methionine amino acid in
the EGF structure. Despite this, these amino acids are not
exposed on the surface of the EGF moiety; therefore these
amino acids are not accessible binding sites to interact
with the AuNPs.2254 According to the current results, both
zeta potential (surface charge variations) and XPS analy-
sis (displacement of binding energies) determine that the
coupling of AuNPs (passivated with citrate) with the EGF
occurs mainly as electrostatic interactions.
One of the biggest advantages of using AuNPs coupled
to biomolecules is their excellent biocompatibility,56 due
to the weak interactions that AuNPs have with some pro-
teins and amino acids in vivo.5556 A high percentage of
these AuNPs is cleared by the mononuclear phagocyte sys-
tem (macrophages),5758 and only a low amount of AuNPs
(about 3%) is accumulated in the liver and very high con-
centrations are required to produce hepatotoxicity.48 Due to
the binding of the EGF is electrostatic, the use of AuNPs
as drug carriers is promising. Hence, the bionanocompos-
ite AuNPs-EGF has a great potential to use for treatment
in diseases where EGF could act as treatment, for exam-
ple, in multiple sclerosis or demyelinating diseases. How-
ever, further studies in vivo are required to determine other
biological aspects, such as biodistribution, dosing and pos-
sible side effects in the organism.
4. CONCLUSIONS
AuNPs with a less than 10 nm diameter were synthe-
sized by the citrate method and coupled successfully to
the EGF. The bionanocomposite (AuNPs-EGF) was sat-
isfactorily characterized ultraviolet-visible spectroscopy,
infrared spectroscopy, transmission electron microscopy,
X-ray photoelectron spectroscopy and zeta-potential. The
main interactions of the AuNPs and the cationic moieties
in the EGF protein were identified as electrostatic in nature
by means of X-ray photoelectron spectroscopy (XPS).
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